The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Mylan Announces XELODA® Settlement and License Agreement

26-Sep-2011 | Source : | Visits : 9093
PITTSBURGH - Mylan Inc. announced in a press release that it has entered into a settlement and license agreement with Hoffman La Roche Inc. resolving litigation related to XELODA® Tablets, 150 mg and 500 mg, USP, known generically as Capecitabine Tablets. This product is an orally administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. 

Pursuant to the agreement, the litigation was dismissed on Sept. 21, 2011. Additional details are confidential, and the agreement itself is subject to review by the US Department of Justice and the Federal Trade Commission. XELODA had US sales of $570 million for the twelve months ending June 30, 2011, according to IMS Health. 

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories.

Related Articles